Advertisement

Atenolol

  • Adam Schneeweiss
  • Gotthard Schettler
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 72)

Abstract

Atenolol is a beta-adrenoreceptor blocker with relative selectivity for beta-1 receptors. It is devoid of local anesthetic activity and intrinsic sympathomimetic activity, and its lipid solubility is very low. Like other beta-adrenoreceptor blockers, atenolol is effective in treatment of angina pectoris, systemic hypertension, and cardiac arrhythmias. It reduces ischemic pain in patients with acute myocardial infarction. The cardioselectivity of atenolol disappears at high concentrations. Therefore, although it may be safer than nonselective beta-blockers in patients with pulmonary obstructive diseases or peripheral vascular disease, this safety is only relative.

Keywords

Acute Myocardial Infarction Angina Pectoris Plasma Renin Activity Systemic Arterial Pressure Elderly Hypertensive Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cruickshank JM: Beta-blockers, bradycardia and adverse effects. Acta Therapeutica 7:309, 1981.Google Scholar
  2. 2.
    Thompson DS, et al: Haemodynamic and metabolic effects of atenolol in patients with angina pectoris. Br Heart J 43:668, 1980PubMedCrossRefGoogle Scholar
  3. 3.
    Amende I, et al: The effects of beta-blocker atenolol and nitroglycerin on left ventricular function and geometry in man. Circulation 60:836, 1979.PubMedGoogle Scholar
  4. 4.
    Jackson G, et al: Atenolol: once-daily cardioselective beta-blockade for angina pectoris. Circulation 61:555, 1980.PubMedGoogle Scholar
  5. 5.
    Harrison DC: Circulatory effects and clinical uses of beta-adrenergic blocking drugs. Ex-cerpta Medica, Amsterdam, 1972, p 142.Google Scholar
  6. 6.
    McDevitt DG, et al: Investigation of chronic dosing regimens of atenolol. Postgrad Med J [Suppl 3] 53:79, 1977.Google Scholar
  7. 7.
    Godenir JP, et al: Atenolol in unstable angina. Drugs [Suppl 2] 25:172, 1983.CrossRefGoogle Scholar
  8. 8.
    Maistrello I: Hypertensive patients treated with atenolol: an overall assessment index. Drugs [Suppl 2] 25:69, 1983.CrossRefGoogle Scholar
  9. 9.
    Douglas-Jones AP, Cruickshank JM: Once-daily atenolol in patients with mild or moderate hypertension. Br Med J 1:990, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Petrie JC, et al: Clinical studies with atenolol in hypertension. Postgrad Med J [Suppl 3] 53:173, 1977.CrossRefGoogle Scholar
  11. 11.
    Alicandri CL, et al: Atenolol once daily in essential hypertension: a multicenter study. Drugs [Suppl 2] 25:70, 1983.CrossRefGoogle Scholar
  12. 12.
    Floras JS, et al: Ambulatory blood pressure and its variability during randomized double-blind administration of atenolol, metoprolol, pindolol, and long acting propranolol in subjects with mild to moderate hypertension. Drugs [Suppl 2] 25:19, 1983.CrossRefGoogle Scholar
  13. 13.
    Ibsen H, Sederberg-Olsen P: Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sei 44:129, 1972.Google Scholar
  14. 14.
    Freis EG, et al: Hypertension. Am J Med 74:1033, 1983.Google Scholar
  15. 15.
    O’Callaghan WG, et al: Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients. Br J Clin Pharmacol 16:417, 1983.PubMedGoogle Scholar
  16. 16.
    Summa JD: Atenolol in the treatment of elderly hypertensive patients. Drugs [Suppl 2]: 86, 1983.Google Scholar
  17. 17.
    Coope JR: Multicentre trial of treatment of hypertension in the elderly in primary care. Drugs [Suppl 2] 25:87, 1983.CrossRefGoogle Scholar
  18. 18.
    Bühler FR, et al: Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36:653, 1975.PubMedCrossRefGoogle Scholar
  19. 19.
    Siamopoulos K, et al: A combination of chlorthalidone (12.5 mg) and atenolol (50 mg) in the elderly. Drugs [Suppl 2] 25:88, 1983.CrossRefGoogle Scholar
  20. 20.
    Clausen T, Flatman JA: The effect of catecholamines on Na-K transport and membrane potential in rat soleus muscle. J Physiol (Lond) 270:383, 1977.Google Scholar
  21. 21.
    Ramsdale DR, et al: Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. Am Heart J 103:459, 1982.PubMedCrossRefGoogle Scholar
  22. 22.
    Perks WH, et al: Atenolol. Br J Clin Pharmacol 5:101, 1978.PubMedGoogle Scholar
  23. 23.
    Butland RJA, et al: Atenolol. Thorax 35:233, 1980.Google Scholar
  24. 24.
    Perks WH, et al: The effects of atenolol in patients with severe chronic airflow obstruction. Drugs [Suppl 2] 25:225, 1983.Google Scholar
  25. 25.
    McAinsh J: Clinical pharmacology of atenolol. Postgrad Med J [Suppl 3] 53:74, 1977.Google Scholar
  26. 26.
    Harron DWG, et al: Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, Sotalol and metoprolol. Clin Pharmacol Ther 29:295, 1981.PubMedCrossRefGoogle Scholar
  27. 27.
    Shanks RG, et al: Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J [Suppl 3] 53:70, 1977.Google Scholar
  28. 28.
    Heel RC, et al: Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17:425, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Fitzgerald JD: The biological and clinical effects of atenolol (“Tenormin”), a cardioselective beta antagonist. In: Pharmacological and biochemical properties of drug substances, vol 2, 1978.Google Scholar
  30. 30.
    Hansson L, et al: Hypotensive action of I.C.I. 66,082, a new beta-adrenergic blocking agent. Int J Clin Pharmacol 10:206, 1974.PubMedGoogle Scholar
  31. 31.
    Cruickshank JM, et al: Beta blockers and the central nervous system (CNS) [abstr]. In: 6th scientific meeting of the International Society of Hypertension, Goteborg, Sweden, 1979.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  • Gotthard Schettler
    • 2
  1. 1.Geriatric Cardiology Research FoundationTel-AvivIsrael
  2. 2.Department of MedicineUniversity of HeidelbergGermany

Personalised recommendations